Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:541656.
doi: 10.1155/2012/541656. Epub 2012 Sep 9.

Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer

Ken-Ichi Tabata  1 , Yuzuru Niibe, Takefumi Satoh, Hideyasu Tsumura, Masaomi Ikeda, Satoru Minamida, Tetsuo Fujita, Daisuke Ishii, Masatsugu Iwamura, Kazushige Hayakawa, Shiro Baba
Affiliations

Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer

Ken-Ichi Tabata et al. Pulm Med. 2012.

Abstract

Purpose. To retrospectively evaluate the clinical significance of radiotherapy for oligometastases of bone in prostate cancer (PCa). Methods and Materials. Between 2003 and 2008, 35 PCa patients with oligometastases of bone were treated with radiotherapy. Results. The median radiotherapy dose was 40 Gy. The 3-year overall survival rates for all patients, for patients that received a radiotherapy dose of ≥40 Gy (n = 21) and for those that received <40 Gy (n = 14), were 77.2%, 90.5%, and 50.0%, respectively. Fourteen out of 16 patients (87.5%) who had pain were improved 1 month after radiotherapy. The median duration of pain relief was 12 months. Pathological fracture and spinal cord compression (SCC) were not seen at the treated sites but developed at nonirradiated sites in three patients (8.6%) and in one patient (2.8%), respectively. Although the high-dose group (≥40 Gy) achieved better survival than the low-dose group (<40 Gy), it was not independent prognostic factor in multivariable analysis. Conclusions. Radiotherapy of bone oligometastases in PCa was effective for long-term pain relief. Pathological fracture and SCC were not seen at the treated sites. A larger clinical trial is warranted to study the actual benefit following radiotherapy for oligometastases of bone in PCa.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The overall survival curves for all patients (n = 35) and those that received a total radiotherapy dose of ≥40 Gy (n = 21) or <40 Gy (n = 14). RTX, radiotherapy.
Figure 2
Figure 2
The overall survival curves for oligo-recurrence group (n = 18) and oligometastases group (n = 17). RTX, radiotherapy.
Figure 3
Figure 3
The progression-free survival curves for patients with bone pain who had pain relief response at 1 month after radiotherapy (n = 14) and with received total radiotherapy dose of ≥40 Gy (n = 7) and <40 Gy (n = 7). RTX, radiotherapy.
See this image and copyright information in PMC

References

    1. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. Journal of Urology. 2000;164(4):1248–1253. - PubMed
    1. Pelger RCM, Soerdjbalie-Maikoe V, Hamdy NAT. Strategies for management of prostate cancer-related bone pain. Drugs and Aging. 2001;18(12):899–911. - PubMed
    1. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195–202. - PubMed
    1. Koswig S, Budach V. Recalcification and pain relief following radiotherapy for bone metastases. A randomized trial of 2 different fractionation schedules (10 × 3 Gy vs 1 × 8 Gy) Strahlentherapie und Onkologie. 1999;175(10):500–508. - PubMed
    1. Steenland E, Leer J, Van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiotherapy and Oncology. 1999;52(2):101–109. - PubMed